NCT03915626View on ClinicalTrials.gov

Effect of Heat on Rivastigmine TDS Products

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Bioavailability
Interventions
DRUG

Rivastigmine (RLD) transdermal patch

brand name patch

DRUG

Rivastigmine (generic) transdermal patch

generic patch

Trial Locations (1)

21201

General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

University of Maryland, Baltimore

OTHER

NCT03915626 - Effect of Heat on Rivastigmine TDS Products | Biotech Hunter | Biotech Hunter